From step counters to soft medical devices
Wearable FDA regulation is increasingly defining whether a wristband or smart ring is treated as a lifestyle gadget or as a clinical health tracking device subject to medical rules, and companies like Whoop and Oura are using that dividing line to reposition themselves as healthcare platforms rather than consumer electronics brands.
The pivot is not subtle. These brands are wiring medication logs, lab uploads and electronic health records into products that once sold sleep scores and strain badges. In doing so, they are testing how far they can stretch into healthcare without triggering full medical-device obligations. That tension is now central to the business model: stay close enough to clinical-grade health tracking to be taken seriously by doctors and pharma companies, but far enough from formal diagnosis to keep innovation cycles fast and liability limited. Consumers may think they are buying wellness wearables; in reality, they are entering softly regulated health infrastructures built around continuous data, behavior change and long-term treatment support.
Whoop’s blood pressure win: a regulatory line in the sand
Whoop’s clash with regulators over blood pressure monitoring wearables shows how language, not sensors, now determines what counts as a medical device. Last August, regulators contacted the company about concerns with its blood pressure analysis feature on its MG wearable and warned that the Blood Pressure Insights tool looked like an uncleared medical device. Whoop pushed back and never turned the feature off, even as negotiations dragged on. The device, part of the higher-end Life plan starting at USD 359 (approx. RM1,650) per year, depends on a conventional cuff for baseline readings and then estimates changes from its own sensors.
Regulators have now issued a closeout letter saying they do not intend to enforce device rules if Whoop modifies the feature, and they have formally allowed the blood pressure tool to stay. The catch: Whoop must strip out diagnostic-style labels and present the feature as wellness insights, with a redesigned interface that removes discrete blood pressure categories. That may look like a cosmetic tweak, but for users it prevents the entire feature from being shut down and preserves continuous blood pressure-related feedback that could inform daily choices. This is the blueprint: reword features until they sit just on the wellness side of wearable FDA regulation, while quietly expanding health monitoring capabilities.
Whoop’s healthcare play: from athletes to clinicians
Regulatory pressure has not pushed Whoop back into safe, fitness-only territory; it has had the opposite effect. The company is doubling down on clinical health tracking by building tools and pricing that target professional caregivers. It recently launched a subsidy program for healthcare workers, offering a 50% discount on new Life memberships and 12‑month extensions through August 31, explicitly pitched as support for clinicians in physically and mentally demanding roles. The goal is clear: turn doctors and nurses into power users who experience in their own bodies how strain, sleep and recovery patterns link to long shifts and chronic stress.
This move sits on top of Whoop Advanced Labs blood testing, new Specialized Panels and integration of electronic health records into the app. Users can align recovery, strain, sleep and performance metrics with chronic conditions, procedures or medication changes, unlocking more personalized recommendations inside a single health platform. A planned collaboration with HealthEx will connect medical records and biometric data in one secure environment, explicitly aiming to bridge wearable data and clinical information. The message to healthcare is provocative: Whoop does not need to be a regulated diagnostic device to influence care decisions; it only needs to be present, credible and interoperable in everyday workflows.
Oura’s GLP‑1 gambit: wearables as medication companions
While Whoop wrestles with blood pressure monitoring wearables, Oura is quietly turning its ring into a digital companion for one of the biggest drug categories in history. Through a partnership with Eli Lilly’s LillyDirect platform, Oura is sending free ring sizing kits and device savings to GLP‑1 users, effectively subsidizing the hardware for people on weight‑loss and metabolic therapies. Forecasts suggest more than 100 million people worldwide could be using GLP‑1 therapies by 2030, and over half of Oura members already identify as having obesity or being overweight, with tens of thousands logging GLP‑1 use in the app.
Oura’s GLP‑1 Insights feature lets members log doses, side effects, weight changes and related biometrics, while Lab Uploads brings blood biomarkers into the same interface as sleep, recovery and activity data. The pharma–wearable partnership aims to blend medication access with behavioral health tools along the full care journey, shifting attention from scale weight to patterns in sleep, recovery and daily habits. This is more than a marketing tie‑in; it is the beginning of a GLP‑1 companion economy, where wearables monitor the “time between prescriptions” and help maintain adherence and lifestyle changes. It is also a direct challenge to the idea that medication management belongs only in clinical settings.
The new deal: pharma alliances and the quiet medicalization of wearables
Taken together, these moves show that pharma wearable partnerships are not side projects; they are strategic bets on the future of healthcare data. Oura and Whoop are integrating healthcare into their product features and branding to bridge biometric tracking and clinical care, using pharma and health‑platform alliances to gain legitimacy as quasi‑clinical tools. One collaboration connects ring users to GLP‑1 medication platforms; another ties a screenless wearable to electronic health records and personalized panels. According to one longevity‑focused outlet, the most revealing aspect is that the boundaries between medicine, technology and everyday behavior are becoming increasingly blurred.
This is a deliberate pivot away from fitness‑first branding toward clinical‑grade health tracking without fully embracing diagnostic responsibility. The upside is powerful: users can keep their blood pressure estimation tools, clinicians get continuous context for patient stress and sleep, and GLP‑1 users receive medication‑aware behavior coaching. The risk is that critical health decisions increasingly depend on systems marketed as wellness, not medical devices. The real question is no longer whether wearables will enter healthcare, but whether regulators, clinicians and patients are comfortable with health platforms built on language workarounds and partnership ecosystems instead of formal medical certification.
